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Multidrug resistance in cancer is linked to expression of the P-glycoprotein multidrug
transporter (Pgp, ABCB1), which exports many structurally diverse compounds from cells.
Substrates first partition into the bilayer and then interact with a large flexible binding pocket
within the transporter’s transmembrane regions. Pgp has been described as a hydrophobic
vacuum cleaner or an outwardly directed drug/lipid flippase. Recent X-ray crystal struc-
tures have shed some light on the nature of the drug-binding pocket and suggested routes
by which substrates can enter it from the membrane. Detergents have profound effects
on Pgp function, and several appear to be substrates. Biochemical and biophysical stud-
ies in vitro, some using purified reconstituted protein, have explored the effects of the
membrane environment. They have demonstrated that Pgp is involved in a complex rela-
tionship with its lipid environment, which modulates the behavior of its substrates, as
well as various functions of the protein, including ATP hydrolysis, drug binding, and drug
transport. Membrane lipid composition and fluidity, phospholipid headgroup and acyl chain
length all influence Pgp function. Recent studies focusing on thermodynamics and kinetics
have revealed some important principles governing Pgp–lipid and substrate–lipid interac-
tions, and how these affect drug-binding and transport. In some cells, Pgp is associated
with cholesterol-rich microdomains, which may modulate its functions. The relationship
between Pgp and cholesterol remains an open question; however, it clearly affects several
aspects of its function in addition to substrate–membrane partitioning. The action of Pgp
modulators appears to depend on their membrane permeability, and membrane fluidizers
and surfactants reverse drug resistance, likely via an indirect mechanism. A detailed under-
standing of how the membrane affects Pgp substrates and Pgp’s catalytic cycle may lead
to new strategies to combat clinical drug resistance.
Keywords: P-glycoprotein (ABCB1), phospholipids, detergents, cholesterol,ATP hydrolysis, membrane partitioning,
membrane transport, drug binding
INTRODUCTION
Many human cancers, including breast, kidney, and colon carcino-
mas, leukemias, multiple myeloma, and several pediatric cancers,
develop multidrug resistance (MDR), which is a major obstacle
to chemotherapeutic treatment (1, 2). MDR tumors are cross-
resistant to a broad spectrum of structurally unrelated cytotoxic
drugs, including the Vinca alkaloids (vinblastine, vincristine),
anthracyclines (doxorubicin, daunorubicin), and taxanes. Phys-
iologically, a complex network of ATP-binding cassette (ABC)
proteins is involved in drug detoxification and protection of tis-
sues from xenobiotics, including administered therapeutic drugs.
Three of these ATP-driven drug efflux pumps are widely expressed
in tumors, and have been linked to drug resistance; P-glycoprotein
(Pgp; ABCB1), ABCG2 and ABCC1 (MRP1) (3, 4). Pgp and
MRP1 exist as large single polypeptides, whereas ABCG2 is a
“half-transporter” that functions as a homodimer. Together, these
three proteins are able to carry out efflux of a wide range of anti-
cancer drugs that are in common use clinically. The ability to
inhibit the action of these drug efflux pumps has the potential
to greatly improve the outcome of chemotherapy treatment, and
the development of strategies to achieve this has been ongoing for
many years.
Since Pgp was the first ABC drug efflux pump to be identified
(5), and has been intensively studied for more than 35 years, it is the
one we know most about. Hundreds of Pgp substrates have been
identified over the years, including many clinically used drugs,
chemotherapeutic agents, natural products, linear and cyclic pep-
tides, amphiphiles, and fluorescent dyes (3, 4). The protein displays
basal ATPase activity, which is often (but not always) stimulated by
substrates, and it hydrolyzes ATP to power active transport, gener-
ating a drug concentration gradient across the membrane (6). Pgp
and other ABC transporters are believed to operate by an alternat-
ing access model. The first step in transport involves binding of
drug to the inward-facing conformation from the cytosolic side of
the membrane. This is followed by a switch to the outward-facing
conformation, which reorients the binding site to the extracellular
side, resulting in drug release. ATP hydrolysis provides the energy
for the switch between these two conformations. Despite recent
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progress in determining the high resolution structure of Pgp,
there are still many gaps in our understanding of how the protein
functions at the molecular level.
It was evident some time ago that the host membrane plays
a central role in Pgp-mediated MDR (7, 8), and the complexity
of this relationship has become more apparent as our knowledge
of the protein has advanced. First, the membrane has a profound
effect on Pgp’s lipophilic substrates, affecting both their lipid parti-
tioning and transbilayer movement. Second, many aspects of Pgp
structure (such as its stability and conformation) and function
(including ATP binding, ATP hydrolysis, drug binding, and drug
transport) are especially sensitive to the properties and composi-
tion of the surrounding membrane. It is important to understand
how Pgp function is modulated by membrane properties, since
this may influence transporter activity in tumors. Indeed, MDR
was successfully reversed in vitro simply by altering the biophysical
characteristics of the membrane (9). Changing membrane prop-
erties may thus be a useful approach for clinical reversal of MDR.
The importance of the membrane in drug efflux also suggests
additional approaches for development of new anti-cancer drugs
and modulators with increased clinical effectiveness; for exam-
ple, chemical modification of existing compounds may alter their
interactions with the membrane, and their ability to access Pgp.
If such strategies are to be successful, it is clearly important to
have a detailed understanding of how the properties of the lipid
environment affect all aspects of the Pgp catalytic cycle.
This review focuses on the complexity of the interactions of Pgp
and its substrates with their membrane environment, the effect of
these interactions on many different aspects of Pgp function, and
how understanding them can help shed light on the molecular
details of drug transport. Our current knowledge of Pgp has been
gleaned from both in vitro and cellular studies of the transporter.
The majority of these studies have been carried out with either
rodent Pgp (Chinese hamster and mouse) or the human pro-
tein. The latter is clearly the clinically important homolog, but (as
discussed further below) high resolution structures are currently
available only for the mouse and Caenorhabditis elegans proteins.
The rodent Pgps are highly active, relatively stable, and have proved
extremely useful for in vitro studies of the structure and mecha-
nism of action of the purified protein. The human protein, on the
other hand, appears to be relatively unstable and is more difficult
to express and purify [e.g., Ref. (10)]. The rodent Pgps are very
closely related to the human homolog (e.g., 87% sequence iden-
tity and 93% sequence similarity between Chinese hamster and
human Pgp), and only small differences in substrate specificity
have been observed in cell-based transport assays. Recent work
using purified hamster Pgp in a liposomal assay system to quan-
tify drug interactions reported that results correlated very well with
clinically relevant data on disposition of Pgp transport substrates
in human subjects (11). Rodent Pgps thus remain very important
models for understanding the function of the human protein.
PGP IN HUMAN CANCER: ITS ROLE AND POTENTIAL
MODULATION
P-glycoprotein expression is widespread in clinical cancer. The
U.S. National Cancer Institute uses a panel of 60 tumor cell lines
to identify and evaluate new anti-cancer agents. Expression of Pgp
was detected in 39 of these cell lines, including renal and colon
carcinomas, melanomas, and central nervous system tumors (12).
Expression of Pgp was also highly correlated with resistance of
these cell lines to anti-cancer drugs. Pgp has also been found in
many human tumors (13, 14), with levels often increasing sub-
stantially after one or more rounds of chemotherapy, especially in
acute myelogenous leukemia and lymphomas. Even very low levels
of Pgp that are difficult to detect in tumor tissue significantly affect
the sensitivity of cells to drugs. Although multiple mechanisms are
undoubtedly responsible for drug resistance in vivo (15), Pgp is the
single most important cause of MDR, representing an attractive
target for intervention. Pgp expression has been linked to reduced
responses to chemotherapy and poor clinical outcome for breast
cancer, sarcomas, hematological malignancies such as leukemias,
and pediatric cancers [reviewed in Refs. (1,16)]. An important goal
in cancer therapy has been the development of compounds that
can effectively inhibit Pgp-mediated MDR. Such modulators (also
known as chemosensitizers) have been identified based on their
ability to reverse drug resistance in MDR cells in vitro. Pgp modula-
tors commonly used in biochemical studies include verapamil and
cyclosporin A. Since MDR is probably the single greatest barrier to
successful chemotherapy, the ability to circumvent Pgp-mediated
drug resistance could lead to improved treatment outcomes.
Three different strategies for defeating Pgp have been described
(1); “engage” (co-administration of anti-cancer drugs and modu-
lators), “evade” (the use of anti-cancer drugs that are poor Pgp
substrates), and “exploit” (specific targeting of the Pgp mole-
cule). Many clinical trials have been carried out to evaluate the
hypothesis that co-administration of modulators would improve
the effectiveness of chemotherapy drugs, thus leading to increased
efficacy in patients [reviewed in Ref. (16)]. Early promising results
obtained for pediatric cancers using cyclosporin A (17) generated
optimism that this approach might be useful in tumors where
Pgp expression is the primary cause of MDR. However, success
in adult cancers has been elusive, in part because of poor clini-
cal trial design and patient selection, and also because first and
second generation modulators showed toxicity, sub-optimal effec-
tiveness, and serious pharmacokinetic drug interactions (16, 18,
19). Since then, much more potent and less toxic third generation
modulators have been developed to target Pgp specifically, such as
LY336979 (zosuquidar) and XR9576 (tariquidar). However, they,
too, failed to improve patient outcome in clinical trials [see Ref.
(16)]. Several non-toxic plant natural products have also been pro-
posed as MDR modulators, including curcumin (20), polyphenols
(21), and flavonoids (22), however, these have not yet been tested
in clinical trials. Given the disappointing outcome of the modula-
tor strategy to date, it is not clear whether this line of attack will be
successful. Designing novel approaches to specifically target Pgp
in MDR will require detailed knowledge of the various steps in the
catalytic cycle.
VACUUM CLEANER AND FLIPPASE MODELS FOR PGP
FUNCTION
PGP AS A HYDROPHOBIC VACUUM CLEANER
The compounds that Pgp transports are typically lipophilic, so
they accumulate within the lipid bilayer. Pgp substrates are also
generally amphipathic molecules, and rather than distributing
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uniformly in the hydrophobic core of the lipid bilayer, they align
themselves in the interfacial region. NMR studies have shown that
they tend to concentrate between the lipid headgroup and the first
few carbon atoms of the lipid acyl chains (23). Early work strongly
suggested that Pgp effluxes drugs directly from the membrane,
rather than the aqueous phase (6). Acetoxymethyl ester deriva-
tives of various fluorescent calcium and pH indicators entering
intact cells from the extracellular side are intercepted and extruded
without entering the cytosol (24). A Förster resonance energy
transfer (FRET) study in which the transporter was photolabeled
with the lipophilic probe iodonaphthalene-1-azide showed that
the substrate doxorubicin was present within the membrane close
to Pgp (25). This suggested that Pgp may interact with its sub-
strates within the membrane and subsequently efflux them to the
extracellular medium. These observations and others led to the
proposal by Higgins and Gottesman that the transporter was a
hydrophobic “vacuum cleaner” (Figure 1) responsible for removal
of potentially harmful lipophilic compounds from the membrane
(26). Later work showed that the rate of Hoechst 33342 efflux
by Pgp was directly proportional to the membrane concentration
of the fluorescent dye, but inversely proportional to its aqueous
concentration, supporting the idea that transport takes place from
the bilayer interior (27). In addition, studies employing a deletion
mutant of Pgp showed that the transmembrane (TM) domains of
the transporter were sufficient to bind drug substrates (28). The
vacuum cleaner model is now widely accepted, and was a key con-
cept in our understanding of the relationship between Pgp and its
membrane environment.
Transport studies using reconstituted Pgp, plasma membrane
vesicles, and intact MDR cells showed that several fluorescent
substrates (Hoechst 33342, LDS-751, and a rhodamine derivative)
FIGURE 1 | Hydrophobic vacuum cleaner and flippase models of Pgp
function. In the vacuum cleaner model, drugs partition into the membrane,
spontaneously translocate to the cytoplasmic leaflet, and gain access to the
Pgp substrate-binding pocket from within the bilayer interior. They are
subsequently effluxed into the extracellular aqueous phase. In the flippase
model, drugs partition into the membrane, spontaneously translocate to the
inner leaflet, interact with the Pgp substrate-binding pocket, and are then
flipped to the outer membrane leaflet. The drug concentration will be higher
in the outer leaflet compared to the inner leaflet, and a concentration
gradient is generated when drugs rapidly partition from the two membrane
leaflets into the aqueous phase on either side of the membrane.
were extracted from the cytoplasmic membrane leaflet (29–31).
FRET studies designed to pinpoint the location of the binding
sites for Hoechst 33342 and LDS-751 also showed that they were
situated within the TM regions of Pgp, in the cytoplasmic leaflet
of the membrane (32, 33). The recent X-ray crystal structures of
Pgp from mouse (34) and C. elegans (35) have allowed a closer
view of the potential routes that substrate molecules may follow
from the bilayer inner leaflet into the binding pocket of the protein
(see below).
PGP AS A DRUG AND LIPID FLIPPASE
P-glycoprotein may be envisaged as expelling its substrates directly
into the extracellular medium, which would have an energy cost for
lipophilic species. The protein has also been proposed to operate
as a drug translocase or flippase (Figure 1), moving its substrates
from the inner to the outer leaflet of the membrane (26). This
mechanism requires that drug molecules have a specific localiza-
tion within each bilayer leaflet, rather than being randomly dis-
tributed in the hydrophobic core. An NMR study of Pgp substrates
and modulators confirmed that this is the case, and showed that
these molecules align with the phospholipid acyl chains (23). After
reaching the outer leaflet, substrates would then either passively
diffuse into the extracellular aqueous phase (a very fast process), or
move back to the inner leaflet by spontaneous flip–flop. In order to
maintain a substrate concentration gradient across the membrane,
the rate of passive transbilayer flip–flop of substrate would need
to be slower than the rate of Pgp-mediated flipping, so that its
concentration remains higher in the outer leaflet. Indeed, the rate
of drug movement between leaflets is variable, and can be quite
slow, with half-times ranging from minutes to hours depending
on the structure of the compound (36, 37). The flippase model
involves delivery of drug to the outer leaflet, followed by rapid
partitioning into the extracellular medium, while in the vacuum
cleaner model, drug is delivered to the extracellular medium, fol-
lowed by rapid partitioning into the outer leaflet. Since the same
equilibrium state is reached in each case, it is not currently possible
to distinguish experimentally between these two models, and they
are not mutually exclusive. Energetic considerations suggest that
release of a dehydrated lipophilic substrate into the outer mem-
brane leaflet would be energetically more favorable than transfer
into the aqueous phase followed by hydration, but it is possible
that both of these locations are accessible to the substrate-binding
pocket of Pgp during the transport process.
There is substantial evidence supporting the flippase model
for Pgp function. Indeed, the protein is able to act as an out-
wardly directed flippase for several fluorescent phospholipid and
glycosphingolipid molecules in both intact cells and reconstituted
proteoliposomes. Cells overexpressing native or recombinant Pgp
showed altered distribution of fluorescent phosphatidylcholine
(PC), phosphatidylethanolamine (PE), and sphingomyelin (SM),
accumulated lower amounts of both short- and long-chain fluo-
rescent phospholipid derivatives, and displayed increased outward
transport of these analogs, which decreased after treatment with
Pgp modulators (38–42). These observations strongly suggested
that the lipids were Pgp substrates. Sharom and co-workers showed
directly that purified Pgp reconstituted into proteoliposomes can
act as a broad-specificity, outwardly directed flippase for a variety
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of both short-chain and long-chain nitrobenzo-2-oxa-1,3-diazole
(NBD)-labeled phospholipids (43). Phospholipids with the flu-
orescent NBD group on both the acyl chain and the headgroup
were translocated. Simple glycosphingolipids, such as glucosyl-
and galactosylceramide were also flipped by reconstituted Pgp,
as was lactosylceramide, although at a greatly reduced rate (44).
Species with headgroups larger than two sugar residues are unlikely
to be substrates. Like drug transport, phospholipid and glycolipid
flippase activity required ATP hydrolysis, and was inhibited by the
phosphate analog, ortho-vanadate. Flippase activity was inhibited
in a concentration-dependent manner by known Pgp substrates,
and inhibitory potency was highly correlated with their Pgp bind-
ing affinity, suggesting that drugs and membrane lipids follow the
same route through the transporter. Taken together, these observa-
tions suggest that Pgp-mediated drug efflux probably takes place
by a flippase-like mechanism.
INTERACTION OF LIPIDS AND LIPID-LIKE MOLECULES WITH PGP
Eckford and Sharom (45) used several functional screens to iden-
tify a number of lipid-based molecules that interact directly with
Pgp with high affinity (Figure 2). These compounds resulted in
inhibition of ATPase activity, competition for transport of two
drugs, and competition for translocation of NBD–PC (16:0, 6:0),
suggesting that they are substrates for Pgp. Included in these lipid
species are platelet-activating factors (PAFs), ether–phospholipid
signaling molecules that are probably endogenous substrates for
the transporter (46, 47). Pgp is also able to bind and transport
hexadecylphosphocholine (also known as miltefosine), an anti-
cancer drug structurally related to PC (48). Other anti-cancer
agents such as the alkyl phospholipids, edelfosine, and ilmofosine,
and the related compounds, D-20133 and D-21266, also interact
with the transporter, leading to resistance (45, 48). In support of
these results, yeast cells expressing Pgp were previously reported to
be resistant to the cytotoxicity of edelfosine (49). Pgp–lipid inter-
actions thus have important consequences for cancer treatment
using these lipid-based drugs.
Metabolic labeling of Pgp, followed by purification and organic
solvent extraction, was used to isolate and identify the membrane
lipids closely associated with Pgp (50). These proved to be enriched
in PE and to a lesser extent phosphatidylserine (PS), but contained
little PC or SM, despite the fact that these choline phospholipids
are major components of the plasma membrane from which the
transporter was solubilized. Thus Pgp associates preferentially
with certain phospholipids; in this respect, it is interesting that PE
and PS are enriched in the inner leaflet of the plasma membrane,
whereas PC and SM are found primarily in the outer leaflet.
A recent mass spectrometry (MS) study (51) examined lipid
interactions with Pgp using purified mouse protein in micelles
of the detergent n-dodecyl-β-d-maltoside (DDM). Gas phase Pgp
ions were released and retained only one to two detergent mol-
ecules, possibly in the binding pocket. MS could detect simul-
taneous binding of lipids, drugs, and nucleotides. Estimates of
apparent K d values, which were in the micromolar range, indicated
that negatively charged lipids bind to Pgp more favorably than
zwitterionic lipids, and both steric effects and headgroup charge
modulated binding. Binding of the cyclic peptide, cyclosporin A,
was observed to promote subsequent lipid binding. Interestingly,
cardiolipin, a bulky anionic mitochondrial lipid, was also able to
bind to Pgp. It was suggested that lipid molecules could interact
with the transporter inside the large binding cavity and also at
the interface between the protein and the lipid bilayer. This novel
approach shows promise in the direct study of drug and lipid
interactions with Pgp.
PHYSIOLOGICAL ROLE OF PGP–LIPID FLIPPASE ACTIVITY
The physiological significance of Pgp’s lipid flippase activity is still
the subject of speculation. The protein may be the primary means
of exporting PAFs in vivo, by translocating them from the cyto-
plasmic to the extracellular membrane leaflet, from which they
can diffuse into the aqueous external environment. Other proba-
ble endogenous Pgp substrates include steroid hormones such as
aldosterone (52) and β-estradiol-17β-d-glucuronide (53). Indeed,
the transporter is known to interact with several steroids (54, 55),
and a role in transporting these hormones could explain Pgp
expression in the adrenal gland. Pgp may also play a physiolog-
ical role in the biosynthesis of complex glycosphingolipids in the
Golgi by translocating glucosylceramide from the cytoplasmic to
the luminal membrane leaflet. The protein most closely related to
Pgp, ABCB4 (78% sequence similarity), acts primarily as a PC-
specific flippase in the liver, exporting phospholipid into the bile
(56, 57), although it can also transport some drugs at a low rate
(58). Thus Pgp and ABCB4 may function in a similar manner.
It seems unlikely that the primary role of Pgp in vivo is that
of a lipid flippase, because the rate of flipping is relatively low
(43, 44), and Pgp could not rescue a knockout of ABCB4, even
when both proteins were expressed in the liver canalicular mem-
brane (59). However, differing expression levels of each protein
could confound this observation. Another consideration is the
existence of the plasma membrane aminophospholipid translo-
case, ATP8a1, which is a member of the P4-ATPase family. This
protein normally translocates PE and PS to the inner leaflet, thus
maintaining bilayer asymmetry (60). If Pgp moves these endoge-
nous lipids from the inner to the outer leaflet at a significant rate,
it would counteract the action of the translocase, resulting in a
futile cycle of phospholipid flip–flop accompanied by wasteful
hydrolysis of ATP.
Other mammalian ABC superfamily members are known to
operate as physiological lipid transporters or flippases (61–63).
Three proteins in the ABCA subfamily (ABCA1, ABCA7, and
ABCA4) were shown to translocate fluorescent phospholipids in
reconstituted systems (64). ABCA1 and ABCA7 transported lipids
from the cytoplasmic to the extracellular leaflet, whereas ABCA4
is the only known eukaryotic ABC protein to move substrate in
the opposite direction.
PGP STRUCTURE
Like other ABC proteins, Pgp comprises two homologous halves,
each consisting of six TM segments, and two nucleotide-binding
(NB) domains on the cytosolic side where ATP binds and is
hydrolyzed (Figure 3A) (65, 66). The NB domains of ABC pro-
teins contain three highly conserved sequences; the Walker A and
B motifs (found in many ATP-binding proteins) and the C (or
ABC signature) motif that is unique to this superfamily (67).
It is now clear that nucleotide binding to ABC transporters is
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FIGURE 2 | Structures of some lipid-based Pgp substrates.
driven by dimerization of the NB domains (66, 68), which is
essential for ATP-driven transport. The X-ray crystal structures
of several isolated NB subunits of bacterial ABC proteins showed
an interdigitated head-to-tail arrangement, a so-called sandwich
dimer. Two ATP molecules are bound at the interface of the sand-
wich dimer, each interacting with the Walker A and B motifs
of one NB domain and the C motif of the partner domain.
These stable symmetric dimers are only observed when the NB
domains are in an inactive state, either by mutation of an amino
acid residue essential for catalysis, or in the absence of Mg2+
(69, 70). Thus, they probably do not represent a true catalytic
intermediate.
Early electron microscopy (EM) studies provided the first
glimpses of Pgp’s three-dimensional structure [reviewed in Ref.
(71)]. A medium-resolution EM structure of Chinese hamster
Pgp at 8-Å resolution was obtained by cryo-electron crystallog-
raphy of two-dimensional crystals (72). The protein contained
bound nucleotide (AMP-PNP), and showed an asymmetric con-
formation. Other EM studies showed that the two NB domains of
Pgp are closely apposed, leading to a closed conformation that was
attributed to a sandwich dimer (73, 74).
In the past few years, important advances have been made in
understanding the nature of the Pgp-drug-binding pocket [e.g.,
Ref. (32, 33, 75, 76)]. Mutagenesis studies suggested that the pocket
was located at the interface between the two TM halves (77), and
this was later confirmed by photoaffinity labeling in conjunction
with MS (78, 79). The first X-ray crystal structures of mouse Pgp
in an inward-facing conformation appeared in 2009 (34). The
structures were determined in the absence of nucleotide, with and
without bound cyclic peptide substrates, which are located in a
drug-binding pocket within the TM regions of the protein. This
large flexible cavity is made up of two bundles of six helices, each
composed of portions from both the N- and C-terminal halves
(Figure 3B). This phenomenon, known as domain swapping, has
also been reported for other ABC exporters. The pocket is accessi-
ble from the cytoplasmic leaflet of the membrane, as expected.
The drug-binding region is partially lined with aromatic and
hydrophobic residues, which are proposed to bind substrates via
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FIGURE 3 |Topology and X-ray crystal structures of Pgp. (A) The
membrane topology shows two homologous halves, each with six TM
segments and a NB domain on the cytoplasmic side, which binds and
hydrolyzes ATP. (B) X-ray crystal structure of mouse Pgp (34) shows an
inward-facing conformation in the absence of nucleotide (PDB 3G61).
(C,D) The drug-binding pocket of mouse Pgp as seen in the X-ray crystal
structure. (C) Close-up view (4.4 Å resolution) of one molecule of the cyclic
peptide modulator QZ59-RRR (magenta, space-filling format) occupying the
middle site inside the drug-binding pocket, with the volumes of nearby
side-chains shown in gray (PDB 3G60). (D) Close-up view of two molecules of
the cyclic peptide modulator QZ59-SSS occupying the upper and lower sites
(yellow and red, respectively, space-filling format) inside the drug-binding
pocket, with the volumes of nearby side-chains shown in gray (PDB 3G61).
hydrophobic and van der Waals interactions. Different stereoiso-
mers of the same cyclic peptide substrate are held in different
sub-sites by a unique set of interactions, and two molecules of the
same substrate can fit into the pocket simultaneously, via different
sets of interactions (Figures 3C,D). The presence of overlapping
sub-sites inside the binding pocket helps to explain the extraordi-
nary range of chemical structures that interact with Pgp. Although
the mouse structures are not of very high resolution, they provided
some useful information that will help to guide future studies.
However, they have not settled any of the outstanding controver-
sies in the field, such as the extent of the separation and movement
of the NB domains during the catalytic cycle. Some new mouse
Pgp structures show wider separations of the two NB domains
(80). One structure shows a complex with a nanobody inhibitor,
which appears to inhibit ATP hydrolysis by binding to an epitope
on the N-terminal NB domain, thus preventing dimerization of
the two domains.
A higher resolution structure (3.4 ∆) of C. elegans Pgp
in an inward-facing conformation, without bound substrate or
nucleotide, appeared in 2012 (35). It shows a portal leading from
the cytoplasmic side of the bilayer to the central cavity where sub-
strates are presumed to bind. This structure is compatible with
decades of biochemical analysis on the human protein, and helps
to explain perplexing functional data on the Phe335Ala mutant.
Homology models of human Pgp derived from the C. elegans and
mouse Pgp structures differ significantly in their orientation of TM
helices 3–5, and recent work suggests that the C. elegans model is
most likely correct (81).
Recent simulation studies of mouse Pgp in a model membrane
showed a wide range of NB domain separations, underscoring the
apparent high flexibility of the inward-facing protein conforma-
tion (82). Of great interest is the observation that the acyl chain of
a membrane lipid slid into the cleft between TM helix 4 and TM
helix 6, and remained there for the duration of the 50-ns simu-
lation. The tip of the penetrating chain, which was more than 10
carbon atoms long, made contact with several amino acid residues
lining the substrate-binding pocket that are known to be involved
in drug binding. It is possible that the binding pocket of Pgp
may be occupied by endogenous membrane phospholipids in the
absence of drug substrates, in line with the idea that it also func-
tions as a low activity lipid flippase. Occupation of the binding
pocket by lipids might also explain the high basal ATPase activ-
ity observed for Pgp from mouse and Chinese hamster. If these
lipids bind with relatively low affinity, they may be displaced by
high affinity drug substrates, which would thus be transported
preferentially.
To date, only inward-facing conformations of Pgp have been
obtained using crystallographic studies, and there is still no
nucleotide-bound structure available. Until these two “missing
links” are obtained, it will be difficult to make progress on under-
standing the structural changes that take place during the cat-
alytic and transport cycles. The difficulty in crystallizing Pgp
in the outward-facing or nucleotide-bound forms might arise
from either the high dynamic flexibility or low stability of these
conformations.
MODEL SYSTEMS FOR STUDYING THE INTERPLAY BETWEEN
PGP AND LIPIDS
The vacuum cleaner and flippase models predict that Pgp will be
very sensitive to its membrane microenvironment. Because of the
complexities of intact cells, they have limited usefulness in explor-
ing the relationship between transporter function and membrane
properties. Plasma membrane fluidity can be altered by growing
cells in medium containing saturated fatty acids, which alters the
endogenous lipid composition of cellular membranes. Membrane
properties can also be changed by adding exogenous amphiphiles,
or membrane rigidifying or fluidizing agents [e.g., Ref. (9)]. Exper-
imental observables are typically restricted to indirect measures of
Pgp function, such as total cellular drug uptake, or cell survival in
the presence of drug.
Simpler model systems have provided unique opportunities
to explore the structure and function of Pgp. Mammalian MDR
cell lines selected with cytotoxic drugs can express very high lev-
els of Pgp [up to 30% of the total plasma membrane protein
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(83)], and have been popular choices as the starting material
for model systems. Sealed inside-out plasma membrane vesi-
cles have been used for studies of ATP-driven drug transport
[see Ref. (6)], and also as a source of purified active protein
for biochemical and spectroscopic characterization. These stud-
ies have typically relied on the use of exogenous agents to alter
membrane fluidity. For example, the ability of Pgp in canalicular
membrane vesicles to transport daunorubicin and vinblastine was
reduced two- to four-fold by benzyl alcohol, a known membrane
fluidizer (84).
Several research groups have reported successful purification
of Chinese hamster, mouse, and human Pgp from drug-selected
MDR cell lines, or cells expressing recombinant protein [reviewed
in Ref. (6)]. The use of solubilizing detergents is clearly essential in
the extraction and purification of Pgp from native cell membranes.
The choice of detergent is a critical step, and is typically gov-
erned in the first instance by the necessity of maintaining various
functions of the protein, including ATP binding, ATP hydroly-
sis, drug binding, and drug transport. A second consideration
is the compatibility of the chosen detergent with reconstitution,
if this is a desired goal (85). Detergents with very low critical
micelle concentrations (CMCs), such as Triton X-100, are usually
very difficult to remove by dialysis, gel filtration chromatogra-
phy, or dilution, and are not a good choice for reconstitution.
The mild detergents 3-[3-(cholamidopropyl) dimethyl amino]-1-
propanesulfonate (CHAPS) and octyl-β-d-glucoside (OG) have
relatively high CMC values, and have been used successfully
for purification and functional reconstitution of both Chinese
hamster and human Pgp from mammalian cells (86–89).
Purified Pgp of mouse or Chinese hamster origin typically dis-
plays high levels of both basal and drug-stimulated ATPase activity
(2–3µmol/min/mg), and can carry out ATP-dependent active
transport of drugs and hydrophobic peptides after reconstitution
[summarized in Ref. (90)]. However, the basal rate of ATP hydrol-
ysis of purified human Pgp is much lower than that of the rodent
proteins, and it appears to require the presence of both drug sub-
strates and lipids for activity. The rodent and human proteins are
highly homologous, and the underlying reason for this difference
in behavior is not clear. Human Pgp was recently reconstituted
into lipid nanodiscs composed of Escherichia coli lipids, where it
retained robust levels of both basal and drug-stimulated ATPase
activity (91). Surface plasmon resonance was used to probe con-
formational changes in Pgp associated with progression through
the ATP hydrolysis cycle. This novel nanodisc platform may prove
useful in the further study of human Pgp.
Many of the purified Pgp preparations described in the lit-
erature employ the addition of exogenous lipids to maintain its
function. Very few research groups have isolated Pgp in the absence
of added exogenous lipids (50, 92). This approach allowed the
development of experimental protocols to reconstitute Pgp into
proteoliposomes of defined phospholipids, either synthetic or
natural mixtures (92–94). Using these model systems has permit-
ted detailed investigation of how Pgp function is modulated by
membrane properties, leading to unique insights into transporter
behavior. Further details of these studies are provided below.
DETERGENT INTERACTIONS AND EFFECTS ON PGP
FUNCTION
The interaction of Pgp with detergents has been examined from
two different aspects. First, the effectiveness of different deter-
gents in solubilization and functional reconstitution of Pgp has
been studied by several groups. Coupled with this has been the
investigation of how exposure to various detergents stabilizes or
destabilizes the protein. Second, the role of detergents as specific
Pgp substrates and modulators has been explored, with a view
to probing the nature of their interactions with the drug-binding
pocket.
Sharom and co-workers established a protocol for partial
purification of Chinese hamster Pgp with high levels of ATPase
activity using the zwitterionic detergent CHAPS (95), in the
absence of any exogenously added lipids. This allowed subsequent
exploration of the effects of various detergents on the protein’s
activity and stability (96). Only the high CMC detergents, CHAPS
and OG, were able to preserve ATPase activity at higher con-
centrations (4 mM for OG, 10 mM for CHAPS), whereas Triton
X-100, digitonin and SDS resulted in complete loss of activity
at 100µM levels. The ability of CHAPS to preserve Pgp ATPase
activity, while other detergents caused loss of activity was later
confirmed by Orlowski et al. (97). They noted that drug stimula-
tion of ATPase activity was restored after dilution of detergent to a
concentration below its CMC. Even after almost complete removal
of CHAPS from purified Pgp by dialysis, 80–90% of the ATPase
activity remained (96), suggesting that the protein still retained
a substantial annual lipid layer around it, which provided pro-
tection from denaturation. Later work used metabolic labeling to
show that highly purified Pgp in CHAPS solution retained 53–
56 tightly bound phospholipids per protein molecule (50). This
amount may be sufficient to surround the TM domains of the
protein, thus assisting in maintaining its native conformation and
function.
The non-ionic detergents DDM and zwittergent 3–12 were
reported to inactivate Chinese hamster Pgp function at low con-
centrations, below their CMCs, while OG inhibited activity in the
millimolar range (98). In all cases, loss of ATPase activity and
reduced drug-binding activity were prevented by the addition of
0.2% w/w of a crude lipid mixture. It was suggested that these
detergents disrupted the lipid–protein interface, which is essen-
tial for Pgp to maintain its functional conformation. Similarly,
the non-ionic n-alkyl-β-d-maltosides and n-ethyleneglycol mon-
ododecyl ethers were reported to reduce Pgp ATPase activity at
concentrations well below their CMC values (99).
Naito and Tsuruo carried out the purification of human Pgp
from MDR K562 cells using a panel of 12 detergents, and assessed
its function following reconstitution into proteoliposomes (100).
They reported that only cholate, glycocholate, and taurocholate
were able to extract the protein and maintain its activity. However,
the measured ATPase and transport activities were extremely low,
likely as a result of protein denaturation during immunoaffinity
elution. The overall conclusion from all of these studies is that
the sensitivity of Pgp to inactivation by detergents depends on the
lipids present in its immediate environment.
www.frontiersin.org March 2014 | Volume 4 | Article 41 | 7
Sharom P-glycoprotein–membrane interactions
P-glycoprotein was reported to be dimeric or multimeric in the
plasma membrane of some MDR cells (101–103), however, the
minimal functional unit of the protein appears to be a monomer
(104). Poruchynsky and Ling reported that detergent extracts
from hamster and human MDR cell lines contained Pgp in an
oligomerized form (105). CHAPS resulted in a high proportion of
oligomerized Pgp, whereas only monomers were found after SDS
treatment, suggesting that the nature of the detergent is impor-
tant in either the formation or preservation of oligomers. Both
Pgp monomers and oligomers appeared functional, in that they
bound photoactive nucleotide and drug analogs. However, other
studies have failed to find any evidence of Pgp dimerization using
both biochemical and genetic approaches (106). The existence and
functional role, if any, of oligomeric forms of Pgp is, therefore, still
not clear.
Doige and Sharom first noted that Triton X-100 stimulated Pgp
ATPase activity at low concentrations and inhibited it at higher
concentrations, suggesting that it interacted specifically with the
transporter (96). Triton X-100 was also observed to inhibit pho-
toaffinity labeling of Pgp by the substrate 3H-azidopine at low con-
centrations (107, 108). It was later confirmed to be a high affinity
substrate for Pgp (K d=~0.4µM) using fluorescence quenching
of purified protein (109). Several cationic amphiphiles, including
the detergents benzalkonium chloride, methylbenzethonium chlo-
ride, cetylpyridinium chloride, and dodecyltrimethylammonium
chloride, also appear to be Pgp substrates (107, 108). Both drug-
selected MDR cells and Pgp transfectants showed cross-resistance
to these compounds, which was effectively sensitized by the modu-
lator verapamil. The synthetic surfactant, nonylphenol ethoxylate,
which is a common component of various household detergents,
was identified as a constituent of human urine, and in vitro stud-
ies confirmed that it is also a Pgp substrate (110). These findings
indicate that the compound is excreted into the urine in vivo by
kidney Pgp, in keeping with the proposed physiological role of the
transporter in elimination of potentially toxic compounds.
Seelig’s group further pursued the idea that detergents may be
Pgp substrates using the non-ionic species Triton X-100, C12EO8
(dodecyloctaglycol), and Tween 80 (polysorbate-80) (111). The
bell-shaped curves obtained for the effect of these detergents on
Pgp ATPase activity suggested that they behaved like substrates,
and interacted directly with Pgp with high affinity (K d values
~1µM). Thermodynamic measurements showed that the ethoxyl
groups of these detergents formed H-bonds with donor amino
acid residues in the TM regions of Pgp, and their binding affinity
increased with the number of these groups. Further investigation
used a large series of polyoxyethylene alkylether detergents with
varying numbers of methylene and ethoxyl residues (CmEOn),
to systematically dissect the role of hydrophobic and H-bonding
in binding of these compounds (112). Thermodynamic parame-
ters indicated that detergent binding to the Pgp substrate cavity is
driven exclusively by H-bonding or weak electrostatic forces, and
not by hydrophobic interactions. Binding to Pgp is only achieved
if the detergent has at least two hydrogen bond acceptor units
within its chemical structure, supporting earlier work that used a
large number of structurally diverse substrates (113). It is ener-
getically unfavorable for the non-polar moiety of the detergent
(the methylene chain) to enter the substrate-binding pocket, and
it likely remains in contact with the hydrophobic lipid bilayer,
where it may assist in flipping of the molecule to the other leaflet
(112). This concept appears counter-intuitive, since the existence
of hydrophobic and aromatic interactions between bound sub-
strates and the surrounding cavity was suggested based on the
X-ray crystal structures of mouse Pgp (34), and many QSAR
studies have also stressed the importance of non-polar groups
in binding to the transporter. However, the primary role of these
groups may actually be to promote partitioning of the substrate
into the bilayer, where it can then gain access to the protein’s
binding cavity.
Some detergents were reported to produce unexpectedly large
down-modulation of Pgp ATPase activity, which was not a result
of membrane disordering (114). The ratio of the free energy of
detergent partitioning into the membrane (from K lip) and the
free energy of detergent binding to Pgp from within the mem-
brane (from K dlip) appeared to control the rate of ATP hydrolysis
induced by the detergent, and probably the rate of its transport.
Deviations from an optimal ratio of these free energies led to
reduced rates of ATP hydrolysis and, by extension, transport. It
was suggested that similar principles apply to drugs that are Pgp
substrates and modulators.
PERTURBATION OF LIPID BILAYERS BY PGP
Early work on drug-selected MDR cell lines indicated that overex-
pression of Pgp led to secondary changes in the properties of their
plasma membrane [summarized in Refs. (107, 115)]. It seemed
likely that insertion of this large hydrophobic protein perturbs the
physiochemical properties of the membrane, especially in cell lines
where Pgp may represent as much as 20–30% of the total plasma
membrane protein (83, 92). Loe and Sharom used the fluorescent
probe merocyanine 540 to examine the local microenvironment
in the plasma membrane of various CHO cell lines expressing Pgp
(107). This negatively charged dye localizes in the outer leaflet of
the plasma membrane, and the extent of its partitioning into mem-
branes depending on the lipid packing density. Increasing levels of
cellular drug resistance led to a progressive shift in the mean cell
fluorescence to lower levels, indicating that the molecular packing
of lipids in the outer leaflet of MDR cells increases with higher
levels of Pgp expression.
The availability of purified Pgp led to further studies in recon-
stituted systems. Differential scanning calorimetry was first carried
out by Romsicki and Sharom, using the synthetic phospholipid
dimyristoyl-PC (DMPC) as the host lipid (116). Inclusion of
increasing mole ratios of Pgp led to a decrease in the melting tem-
perature of the bilayer, T m. The cooperativity of the lipid melting
transition was greatly reduced, and the transition enthalpy, ∆H,
decreased linearly as the Pgp content increased to a lipid:protein
ratio of 16:1 (w/w). Pgp was found to perturb a large number of
bilayer phospholipids, preventing 375–485 of them from partici-
pating in the phase transition. As the Pgp content of the bilayers
increased, the transition enthalpy was observed to increase again,
an effect likely arising from either aggregation/oligomerization of
the transporter, or a change in its mode of interaction with the
bilayer. Oleinikov et al. explored the perturbing effects of Pgp in
its native environment by forming monolayers from membrane
fractions derived from a series of MDR cell lines in which the
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Pgp content varied from 0 to 32% (w/w) (117). Compression
of the Langmuir–Blodgett monolayers showed that 11 and 24%
Pgp decreased monolayer stability without altering the surface
area, while 32% Pgp increased both the stability and the surface
area. Raman spectroscopy indicated that the presence of 32% Pgp
reduced the lipid transition temperature by 7°C, and the number
of perturbed lipids per protein was estimated at 400–500 (117),
thus confirming the results seen in reconstituted systems (116).
Callaghan and co-workers reported that incorporation of Pgp
into bilayers of PC–PE altered their overall fluidity, increased their
permeability to polar compounds, and modified the packing orga-
nization of fluorescent lipid probes (115). The presence of the
transporter also increased the flip–flop rate of short-chain phos-
pholipids between bilayer leaflets, but this did not require ATP
hydrolysis, so it likely takes place by an indirect mechanism.
Similar types of perturbing effects have previously been noted
when other large hydrophobic proteins are inserted into lipid
bilayers [e.g., Refs. (118, 119)]. Effects specific to Pgp may
arise from its oligomerization behavior, and the ability of the
transporter to interact with, and translocate, membrane lipids.
MODULATION OF PGP FUNCTIONS BY THE MEMBRANE
The availability of purified Pgp, both in detergent solution and
reconstituted proteoliposomes, coupled with the development
of biochemical and spectroscopic techniques for assessing many
aspects of Pgp function, have greatly increased our understanding
of the ways in which the lipid environment can modulate the trans-
porter. The catalytic cycle of Pgp involves several steps, including
nucleotide binding, drug binding from within the membrane,
nucleotide hydrolysis, and drug translocation. Each of these steps
may be subject to the influence of the surrounding membrane. In
recent years, greater emphasis has been placed on the importance
of measuring thermodynamic and kinetic constants for the vari-
ous steps, since these provide a sound basis for construction of a
detailed, experimentally testable model of the catalytic cycle.
DRUG-MEMBRANE PARTITIONING
P-glycoprotein substrates are typically lipid-soluble and amphi-
pathic, and it is now clear that their binding to the protein takes
place in two steps: partitioning into the lipid bilayer, followed by
interaction with the substrate-binding pocket located within the
TM domains. The presence of a drug within the membrane inner
leaflet is thus a primary determinant of its recognition by the
transporter. Amphipathic molecules are not randomly distributed
in the bilayer, but orient themselves in an anisotropic manner at
the lipid–water interface, parallel to the long axis of the mem-
brane phospholipids (23, 120, 121). Their polar moieties interact
with water and phospholipid headgroups, and (depending on the
compound) their hydrophobic moieties may enter the non-polar
core of the bilayer. Modeling studies suggest that a specific mol-
ecular conformation may also be required for partitioning of, for
example, verapamil into the bilayer (120).
Since substrates gain access to Pgp from within the membrane,
the lipid–water partition coefficient, K lip, is an important mol-
ecular property affecting their interactions with the transporter.
Lipid bilayers are multilayered, amphipathic structures (essentially
highly ordered liquid crystals), and cannot be readily mimicked
by isotropic systems such as octanol or olive oil. Experimental
measurement of K lip values using lipid bilayers is thus important
for a quantitative understanding of the contribution of substrate
partitioning to interaction with Pgp. K lip values for Pgp substrates,
whose structures are extremely diverse, range from 50 to 105 (111,
112, 114, 122–126). The high lipid–water partition coefficients
of a series of polyoxyethylene alkylether detergents resulted in
their concentration in a palmitoyloleoyl-PC (POPC) bilayer (112).
Calorimetric measurements indicated that lipid partitioning was
an entropy-driven hydrophobic event, driven by release of water
molecules from the detergent when it entered the bilayer.
The passive diffusion and spontaneous flip–flop of small mole-
cules across membranes decline exponentially with an increase in
lateral packing density (127), which in turn depends on lipid com-
position and temperature. Native plasma membranes with high
lateral packing density, such as these found in endothelial cells of
the blood brain barrier, may thus make it easier for Pgp to estab-
lish a drug concentration gradient. Phospholipid bilayers exist in a
rigid gel phase below the phase transition (melting) temperature,
T m, and a fluid liquid-crystalline phase above this temperature.
These two phases are characterized by different packing densi-
ties, diffusion rates, fluidity, and lipid conformations. In an effort
to understand the effects of membrane biophysical properties on
partitioning of Pgp substrates, Clay and Sharom measured K lip for
three structurally unrelated Pgp substrates (LDS-751, H33342, and
MK-571) in DMPC and palmitoylmyristoyl-PC (PMPC) bilay-
ers over a temperature range that spanned T m (122). Membrane
partitioning of all three drugs was greatly favored in the fluid
liquid-crystalline phase relative to the more rigid gel phase. The
volume of the lipid bilayer increases by 4% when it melts (128),
so drugs can fit more easily into the additional space present in
the membrane in the liquid-crystalline phase, resulting in higher
partitioning. The membrane partitioning of these three substrates
was greatly affected by small changes in acyl chain length and lipid
phase state, implying that such changes in membrane properties
can readily modify Pgp’s ability to bind drugs within the bilayer
and transport them to the aqueous phase. Lipid rafts are small
cholesterol- and glycosphingolipid-rich microdomains which dis-
play altered lipid composition, including acyl chain length, and
also exist in a phase with reduced fluidity (the liquid-ordered
phase, lo), compared to the bulk membrane. Pgp appears to be
located within rafts in some cell types (see below), and may move
in and out of them in a dynamic fashion, thus potentially changing
its access to drug substrates within the bilayer.
ATP BINDING AND HYDROLYSIS
Although the NB domains of Pgp are envisaged as being located
in the cytoplasmic compartment, they appear to be almost com-
pletely dependent on the presence of membrane lipids for their
catalytic activity. Early work showed that a Pgp-β-galactosidase
fusion protein required phospholipids for ATPase activity (129).
Detergent delipidation of Pgp results in complete loss of ATPase
activity, which is readily and rapidly reversible by addition of lipids
(96, 98, 130), suggesting that the loss of activity does not involve
denaturation of the protein.
The ability of bulk exogenous phospholipids to protect Pgp
catalytic activity from thermal inactivation was tested by Sharom
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and co-workers, using partially purified Chinese hamster Pgp
in CHAPS solution (96). Asolectin, a mixture of soybean phos-
pholipids, provided complete protection of the ATPase activity
at 0.25 mg/mL, whereas various PC species did not. PS was also
able to maintain the ATPase activity, and various PE species, either
alone or mixed with PC, actually stimulated activity. Restoration of
ATPase activity following detergent delipidation with Triton X-100
and deoxycholate required a different set of phospholipids, likely
reflecting the intimately associated annular lipids that Pgp prefers
(96). In general, short, unsaturated fluid lipids were better able to
restore activity than longer, saturated species. The ATPase activity
of purified Chinese hamster Pgp in CHAPS solution was altered by
incubation with various phospholipids, some of which stimulated
activity, while others caused inhibition (50). The best stimulatory
lipid, dipalmitoyl-PE, was a mixed activator, increasing V max and
decreasing the K M for ATP. Exogenous lipids are probably able
to exchange into the annular lipid region of Pgp in the presence
of small amounts of detergent, thus modulating protein function.
Mixed activation is a common observation with Pgp-drug sub-
strates. The ability of phospholipids to modulate ATP hydrolysis
could also be because they are actually transport substrates, as
discussed previously in the context of the documented flippase
activity of the transporter.
Urbatsch and Senior solubilized Chinese hamster Pgp using
OG and attempted to purify it in the absence of exogenous lipids
(86). This resulted in completely inactive protein that could not be
restored by reconstitution. When Pgp was purified in the presence
of three natural lipid mixtures, activity was maintained, and they
were able to reconstitute it into proteoliposomes of these lipids
(86). They noted different effects on the level of ATPase activ-
ity and its stimulation by drugs, depending on the host lipid. The
level of drug stimulation, which may reflect coupling between drug
binding and ATP hydrolysis, was also reported by other groups to
be increased after reconstitution of Pgp (87, 131), as was high
affinity drug binding (98).
To explore the effects of lipid melting on catalytic activity,
purified Pgp was reconstituted into synthetic phospholipid bilay-
ers with a defined melting temperature, composed of DMPC
(T m=~23(C) and PMPC (T m=~28(C) (132). Both ATP bind-
ing and ATP hydrolysis were found to be modulated by the phase
state of the membrane. The kinetic parameters and activation
energy for ATP hydrolysis, as well as K d for ATP binding, were
significantly different above and below the bilayer melting tem-
perature, and there was a sharp discontinuity at T m. The binding
affinity for ATP was higher in the fluid liquid-crystalline phase,
whereas the K M for ATP hydrolysis was lower in the rigid gel phase.
No changes in these parameters were observed at the same tem-
peratures with Pgp in detergent solution. Thus, the conformation
and/or folding of the NB domains may be affected by the fluidity
and/or packing density of the membrane, which in turn affects
nucleotide binding and hydrolysis. The opposite effects observed
for K d and K M are not contradictory, since these parameters can
only be considered equivalent for a simple Michaelis–Menten reac-
tion scheme, and the catalytic cycle for Pgp is likely much more
complex, with multiple steps.
Using drug-induced modulation of ATPase activity as a surro-
gate measure of drug binding, Seelig and co-workers were able to
estimate the thermodynamic parameters for ATP hydrolysis (133).
They showed that although the membrane lateral packing den-
sity only modulates the overall ATPase activity by up to two-fold,
it substantially affected the thermodynamics of the transporter,
which operated in an enthalpy-driven manner at low packing den-
sities, but was driven by entropy at high densities. Partitioning of
highly lipophilic Pgp substrates into the bilayer, and their accumu-
lation to high concentrations (see above), may increase the fluidity
and reduce the lateral packing density of the membrane. However,
this appears to have only small effects on the thermodynamics of
ATPase activity (133).
A FRET study showed that the NB domains of Pgp lie close
to the membrane surface (134). In addition, when expressed in
E. coli, the C-terminal NB domain was associated with the mem-
brane fraction, indicating that it might interact preferentially with
lipid surfaces (135). Taken together, this suggests that Pgp’s NB
domains may be in physical contact with the membrane surface,
much like peripheral proteins, explaining why membrane fluidity
and packing density affect their function. The lipid requirement
for catalytic activity may be interpreted in two ways. Either the
lipids are needed for stabilization of the TM regions which in turn
stabilize the NB domains, or the NB domains interact with the
membrane directly and require phospholipids for their catalytic
function and, possibly, their structural integrity.
Rodent and human Pgp appear to differ in terms of their stabil-
ity and lipid requirements for activity. The human protein typically
displays very low basal ATPase activity compared to the Chinese
hamster protein, but shows much higher levels of drug-stimulated
activity. Reconstitution into lipid is often necessary for observa-
tion of any ATPase activity at all [for example, see Ref. (136)]. The
drug-stimulated activity of human Pgp also appears to be highly
dependent on the presence of cholesterol (137). Kodan et al. car-
ried out a systematic study of factors promoting the stability of
human Pgp expressed in insect cells (10). They noted a remark-
able stabilizing effect of cholesteryl hemisuccinate (CHS) on the
stability of the protein’s ATPase activity after DDM solubilization;
only 50% of the activity remained after 1 h at 25°C in the absence
of CHS, whereas 50% activity was still present after 30 days at 4°C
in the presence of 0.02% CHS. CHS has been noted to stabilize
other human membrane proteins after DDM solubilization (138).
DRUG BINDING
Measurement of equilibrium drug binding to Pgp in plasma
membrane vesicles from MDR cells has been carried out using
radiolabeled substrates and modulators (139). This approach is
technically difficult because the hydrophobic compounds give rise
to high levels of non-specific background association with the
membrane. Fluorescence spectroscopic methods using purified
Pgp in detergent solution and reconstituted proteoliposomes have
allowed quantitative estimates of K d for binding of many sub-
strates and modulators, without the need to separate free and
Pgp-bound drugs [reviewed in Refs. (140, 141)]. The affinity
of Pgp for binding a large group of compounds with diverse
structures covers a range of ~104, from 37 nM to160µM.
Because of the difficulty of directly assessing drug binding,
several groups have used drug or modulator stimulation of Pgp
ATPase activity as a surrogate measure. Changing patterns of
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substrate-induced ATPase stimulation in the presence of different
lipids suggests that either drug binding itself, or the coupling
between drug binding and ATP hydrolysis, is altered by the mem-
brane environment. Following Pgp purification and reconstitution
into three natural lipid mixtures, Urbatsch and Senior noted dif-
ferent effects on the level of stimulation of ATPase activity by
three substrates and one modulator, depending on the host lipid
(86). Other groups also reported that after reconstitution of Pgp
the level of drug stimulation of ATP hydrolysis (87, 131), and the
affinity of drug binding (98) were increased.
For a substrate to interact with Pgp, two distinct steps must
take place. The drug must first partition from the aqueous phase
into the bilayer, and then it must enter the binding pocket of the
transporter. Seelig and co-workers proposed that Pgp functions
optimally when the free energies for these two processes fall in a
narrow range (114). The first step is defined by the lipid–water par-
tition coefficient for the drug, K lip, and the second step is defined
by the dissociation constant for binding of the drug to Pgp within
the membrane, K dlip (see Figure 4). The apparent binding affinity
of Pgp for drugs measured from the aqueous phase, K d, is related
to K dlip by:
Kdlip = Kd(Vlip
V + 1Klip
)
where V is the total volume of the system, and V lip is the volume
of lipid (122). Thus experimental measurement of K lip and K d
can provide an estimate of the “true” affinity of Pgp for binding
drugs from within the lipid bilayer.
For reconstituted Pgp in three different lipid systems, a high-
fluidity lipid (egg PC) gave a large increase in binding affinity
(determined by fluorescence quenching) compared to a low-
fluidity lipid (dipalmitoyl-PC; DPPC) for vinblastine and vera-
pamil (6- to 15-fold reduction in K d value), while daunorubicin
showed a much smaller change (two-fold reduction) (124). K d
was also correlated with the value of K lip for vinblastine and ver-
apamil. The highest apparent binding affinity was observed for
substrates that had the greatest partitioning into lipid, in other
words, the highest concentration in the bilayer (Figure 4). This
suggests that the bilayer drug concentration is a major determi-
nant of binding affinity, in agreement with the vacuum cleaner
model. Pgp may thus have a relatively low “true” affinity for bind-
ing within the bilayer (i.e., K dlip is high), but the membrane highly
concentrates its substrates. A large fraction of the free energy of
drug binding to the protein from the aqueous phase was shown
to be provided by the free energy of drug–lipid partitioning, on
the order of 75% (122, 126). In concert with changes in bind-
ing affinity, different host lipids also produced an altered ATPase
stimulation profile for verapamil. Higher drug-binding affinity led
to higher levels of stimulation of activity, whereas the concentra-
tion of verapamil required for half-maximal stimulation remained
unchanged (124).
The extent of partitioning of substrates into the membrane is
thus important for their interaction with Pgp, because it essentially
controls the effective concentration presented to the transporter.
For example, the apparent binding affinity of C. elegans Pgp for
FIGURE 4 | Substrate–membrane relationships and their role in drug
binding to Pgp. Pgp substrates partition into the lipid bilayer from the
aqueous phase in accordance with their lipid–water partition coefficients
(K lip). The drug on the left of the figure has a high K lip value and thus reaches
a high concentration in the lipid phase, whereas the drug on the right of the
figure has a low K lip value, and therefore has a much lower membrane
concentration. K lip values measured for Pgp substrates are typically in the
range 300–20,000. The apparent binding affinity (K d) is determined using
aqueous drug concentrations, and depends on both drug partitioning into
the lipid phase and drug binding to the transporter from within the
membrane. The intrinsic affinity of Pgp for binding substrate from the lipid
bilayer (K dlip) can be estimated from the values of K lip and K d, and is
relatively low, in the range 0.5–70 mM.
paclitaxel and actinomycin D was increased 100- and 4,000-fold,
respectively, when the protein was in a membrane environment
compared to detergent solution (35). Seelig and co-workers were
the first to address this idea directly, using the drug concentration
required for half-maximal ATPase stimulation as an indirect mea-
sure of its binding affinity (142). By calculating the free energy of
drug binding from the aqueous phase to Pgp in the membrane,
and combining this with drug–lipid partitioning data, they were
able to estimate the affinity of Pgp for binding three drugs from
the lipid phase. K dlip values were in the range 0.5–4 mM for three
substrates (142),providing the first evidence that Pgp binds its sub-
strates from the membrane with low affinity. Recent work by Clay
and Sharom using reconstituted Pgp in DMPC and PMPC bilay-
ers directly measured the K d for binding to Pgp from the aqueous
phase, and also the lipid–water partition coefficient for three struc-
turally unrelated substrates (122). Estimated K dlip values were
high, in the range 9–70 mM, confirming that Pgp has an intrinsi-
cally weak interaction with substrates within the lipid bilayer.
Defined reconstituted systems provide a powerful tool to define
the effect of bilayer physicochemical properties on drug binding.
Romsicki and Sharom first made the interesting (and paradoxical)
observation that the binding affinity for vinblastine, verapamil
and daunorubicin was higher in gel phase DMPC bilayers, despite
the fact that drug partitioning is substantially lower for gel phase
lipid (124). More recent work using Pgp reconstituted into DMPC
and PMPC bilayers showed that this relationship held true for the
substrates H33342, LDS-751, and MK-571 (122); both K d and
K dlip values are lower (i.e., binding affinity is higher) in rigid
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gel phase bilayers. Van’t Hoff plots of binding parameters over
a wide temperature range showed different values of the binding
free energy above and below the lipid phase transition. Since sub-
strates must leave the lipid bilayer when they bind to Pgp, a less
favorable drug–lipid interaction would encourage binding to the
transporter. Analysis of the thermodynamic parameters for Pgp-
drug binding in a manner which eliminated the contribution of the
lipid was therefore carried out. Results indicated that both drug–
lipid and drug–Pgp interactions contributed to the overall binding
affinity, which was altered by both acyl chain length and lipid phase
state, depending on the specific drug under consideration.
DRUG TRANSPORT
Early work showed that small molecule fluidizers and surfactants
could reduce Pgp transport function in plasma membrane vesicles
and intact MDR cells, leading to increased accumulation of drugs
and reversal of drug resistance (9, 84, 143–145). Transport inhi-
bition does not appear to involve direct interaction between these
agents and Pgp, and is probably linked to increases in membrane
fluidity or permeability (146, 147).
A transport study using Pgp reconstituted into bilayers of the
synthetic phospholipid DMPC found that ATP-driven transport of
[3H]colchicine into reconstituted proteoliposomes determined by
rapid filtration was more than two-fold higher at the T m of 24°C
than in the fluid liquid-crystalline phase at 32°C (8). Using Pgp in
bilayers of DMPC and PMPC, the effect of bilayer phase state on
the kinetics of ATP-driven transport was explored further (148).
The initial rate of transport of the high affinity substrate tetram-
ethylrosamine (TMR,a rhodamine derivative) was measured using
a continuous real-time fluorescence assay over a time-scale of less
than 1 min. Results showed that drug transport was modulated
by the fluidity of the host membrane, with biphasic temperature
dependence. The transport rate was high in rigid gel phase lipid,
reached a maximum at the melting temperature of the bilayer, and
then declined in fluid liquid-crystalline phase lipid. This behavior
is unusual, as many membrane transport proteins show low or
non-existent transport activity in rigid gel phase lipid, compared
with activity in the fluid liquid-crystalline phase. Rigid gel phase
lipid is poorly compressible, and it is thought that rate-limiting
protein conformational changes are hindered in such an environ-
ment. It is possible that Pgp does not have a conformational barrier
of this nature.
The rate of transport by Pgp likely depends directly on the drug
concentration within the bilayer, and this, in turn, is controlled by
the level of membrane partitioning of the substrate. Thus, the rate
of drug transport may depend directly on the lipid–water parti-
tion coefficient, K lip. Rogers and Davis reported that partitioning
of various p-alkylphenols into DMPC bilayers also showed bipha-
sic temperature dependence (149). The value of K lip showed a
maximum at T m, declined substantially at temperatures higher
than T m, and remained constant, or declined slightly at tempera-
tures lower than T m, a pattern very similar to that seen for TMR
transport by Pgp in bilayers of DMPC and PMPC (148). The tem-
perature dependence of drug transport by Pgp may thus reflect
the temperature dependence of K lip for the substrate.
A recent study examined the effect of bilayer properties on
Pgp-mediated transport of H33342 and LDS-751 in DMPC and
PMPC bilayers, using real-time fluorescence measurements (122).
Membrane partitioning data were also collected for these sub-
strates, which allowed Pgp transport turnover numbers to be
obtained in a reconstituted system for the first time. For both
drugs, there is a clear discontinuity in transport rates above and
below T m, however, in contrast to the previous studies using TMR,
higher transport rates were observed in the liquid-crystalline phase
relative to the gel phase. Different temperature dependence of par-
titioning of the three substrates into gel and liquid-crystalline lipid
bilayers may be responsible for this difference in behavior. LDS-
751 and H33342 displayed the opposite behavior to TMR; their
lipid–water partition coefficients increased with temperature in
liquid-crystalline phase bilayers.
Overall, these studies clearly indicate that the membrane phase
state is an important factor affecting Pgp’s ability to transport
drugs. One proposed strategy for reducing the transport activity
of Pgp, thus reversing MDR, involves modifying the fluidity of
the lipid environment (144). Since the effect of lipid fluidity on
drug transport appears to vary depending on the specific substrate
being transported, such an approach may not be feasible.
INTERACTIONS OF PGP WITH STEROLS
Cholesterol is a major component of mammalian plasma mem-
branes, making up about 50% of the lipid content on a mole basis,
and there have been many observations linking this sterol to Pgp
function. Early work in intact cells suggesting the involvement of
Pgp in cholesterol esterification was plagued by contradictions and
confusion [reviewed in Ref. (123)] resulting from the use of Pgp
modulators that later turned out to also inhibit cholesterol metab-
olism. Drug-selected MDR cells typically show changes in lipid
composition, including cholesterol content, which may inciden-
tally affect Pgp function. A study using cell lines where Pgp was
inducible concluded that expression of the protein does not play a
major role in cholesterol homeostasis (150), and that effects previ-
ously noted in drug-selected cells expressing Pgp might result from
changes in other pathways that accompany selection. However, a
possible physiological role for Pgp in intracellular cholesterol traf-
ficking has been suggested (151). Using Pgp-deficient fibroblasts,
replication of Toxoplasma gondii was shown to be critically depen-
dent on Pgp, which played a role in the transport of host-derived
cholesterol to the intracellular parasite.
Many studies investigating the role of cholesterol in Pgp func-
tion in intact cells and native membrane vesicles made use of
methyl-β-cyclodextrin (MβCD), a cholesterol-extracting agent, to
alter the amount of cholesterol in the plasma membrane (152–
155). Essentially, all the cholesterol can be removed from mem-
branes by this compound at a sufficiently high concentration, and
inclusion complexes of MβCD with cholesterol can also be used
to achieve controlled cholesterol repletion. However, MβCD was
shown to directly inhibit the catalytic activity of Pgp, independent
of its ability to extract cholesterol from membranes (123), calling
into question the conclusions of studies that used this reagent.
Many groups have reported that the presence of cholesterol
affects the catalytic activity of Pgp and its stimulation by sub-
strates and modulators. When mouse Pgp was partially purified
by hydroxyapatite FPLC using SDS, reconstitution into bilayers
without cholesterol was reported to result in four- to five-fold
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reduced ATPase activity relative to bilayers where 20–40% choles-
terol was incorporated (156). In addition, no stimulation of the
activity by verapamil was observed unless cholesterol was included
in the bilayer. Further studies showed that the lipids α-tocopherol
and DPPC could also enhance verapamil stimulation, although
they had no effect on basal ATPase activity (157). However, the
ATPase activity of this Pgp preparation was very low, and it is pos-
sible that it was either partially denatured or not properly folded
because of the somewhat harsh solubilization conditions, which
likely strip away endogenous lipids. Callaghan and co-workers
reported that the basal ATPase activity of partially purified hamster
Pgp in PC–PE liposomes was increased ~two-fold on incorpora-
tion of 0–30% cholesterol (115). The fold-stimulation of ATPase
activity induced by verapamil was reduced at higher cholesterol
levels, although the absolute level of activity increased. Eckford and
Sharom found that cholesterol had only a modest overall effect on
catalytic activity. Purified Chinese hamster Pgp reconstituted into
DMPC bilayers showed a small increase in basal ATPase activ-
ity, but a decrease in the level of verapamil-stimulated activity,
with increasing cholesterol content from 0 to 30% (123). Cho-
lesterol at high concentrations was able to partially restore the
activity of delipidated Pgp, but less effectively than either PC or a
PC-cholesterol mixture. Using purified reconstituted human Pgp,
Kimura et al. reported that increasing cholesterol in the bilayer
from 0 to 20% increased basal ATPase activity and modulated
drug-stimulated activity (137).
However, cholesterol is not strictly required for Pgp function.
Pgp purified using CHAPS is fully active (ATPase activity and drug
transport) in proteoliposomes composed of synthetic phospho-
lipids in the absence of added cholesterol [for example, see Refs.
(122, 123, 132, 148)]. Perhaps this is because CHAPS-purified
Pgp appears to retain an annular phospholipid layer around it
(50). Alternatively, the sterol-like structure of CHAPS may interact
with Pgp in a favorable manner, mimicking cholesterol. However,
CHAPS does not stimulate Pgp ATPase activity like other deter-
gents that are known to be substrates (96). It seems likely that the
effects of cholesterol on both basal and drug-stimulated ATPase
activity will differ depending on the specific detergent used to sol-
ubilize the protein, the extent to which endogenous lipids have
been removed, and the lipid mixture used for reconstitution.
Cholesterol is well known to alter membrane packing, order,
and fluidity. Such changes in the local environment may directly
modulate the ability of Pgp to bind and hydrolyze ATP, and
to transport drugs. Physicochemical changes in the membrane
induced by cholesterol may also affect the concentration of drugs
in the bilayer by changing their lipid–water partition coefficients.
The inclusion of 30% cholesterol in DMPC proteoliposomes
reduced Pgp’s binding affinity for ATP by ~2.5-fold (123). This
is in agreement with a previous report that ATP-binding affin-
ity decreased in bilayers with lower fluidity (132). Photoaffinity
labeling of Pgp by the substrate [3H]azidopine was altered by
yeast sterols, and cholesterol, suggesting that these lipids affected
drug binding (158, 159). Later studies using fluorescence quench-
ing to quantify drug interactions with purified reconstituted Pgp
found that inclusion of cholesterol in the bilayer alters binding
affinity (123, 124). The effects were dependent on the specific
substrate used, with some drugs (e.g., vinblastine) showing a
10-fold increase in K d value as cholesterol levels increased from
0 to 30%, while others (e.g., daunorubicin) showed essentially no
change (123). These complex effects of cholesterol are different
for individual drugs, and may be related to drug–lipid partition-
ing. Eckford and Sharom found that cholesterol had a large effect
on drug partitioning into lipid bilayers, reducing the K lip value
by two- to nine-fold for several common Pgp substrates, with the
exception of Hoechst 33342, which displayed a ~two-fold increase
in K lip (123). These differences may arise from the specific localiza-
tion within the bilayer of drugs and cholesterol, which will modify
the properties of different regions of the membrane selectively.
A water-soluble cholesterol analog, polyoxyethylcholesteryl
sebacate, competed with daunorubicin for binding to Pgp (160),
and cholesterol co-eluted with purified Pgp in detergent (137),
however, it is still not clear whether these interactions are specific.
Using the kinetics of drug-stimulated ATPase activity as a surrogate
measure for drug-binding affinity, Kimura et al. reported that the
presence of cholesterol in reconstituted proteoliposomes increased
Pgp’s binding affinity for small molecular mass drugs (<500 Da),
but not for larger drugs (800–900 Da) (137). They proposed that
cholesterol may occupy the substrate-binding pocket simultane-
ously with smaller drug molecules, filling the empty space and
thus promoting their binding (161). However, when drug bind-
ing to reconstituted Pgp was measured directly using fluorescence
quenching, no relationship between drug size and the effect of
cholesterol on binding affinity was found (123). A large drug
(vinblastine) showed a large reduction in binding affinity at high
bilayer cholesterol, whereas a small drug (daunorubicin) showed
little change in affinity.
The effect of cholesterol on the ability of Pgp to flip fluorescent
NBD–PC and transport three different substrates were explored
in reconstituted proteoliposomes (123). A modest decrease in flip-
pase activity was noted at 20–30% cholesterol, and the ability of
vinblastine to compete for flippase activity was enhanced. Inclu-
sion of cholesterol in the bilayer showed biphasic effects on the
initial rate of transport of TMR and Hoechst 33342. Net transport
into proteoliposomes is a balance between inward active pumping
of substrate by Pgp and passive outward efflux through the bilayer.
These results were explained by cholesterol altering the membrane
permeability and partitioning of substrates, which affect transport
indirectly (123).
Whether Pgp is directly involved in outward movement of
cholesterol across the plasma membrane has been the subject
of debate. The effect of Pgp on the transbilayer distribution of
cholesterol in native membrane vesicles was monitored using cho-
lesterol oxidation by cholesterol oxidase. (152). It was concluded
that Pgp was responsible for ATP-dependent transport of cho-
lesterol from the cytoplasmic to the extracellular leaflet of the
membrane. However, the estimated rate of spontaneous choles-
terol movement between membrane leaflets was very slow, with
a half-time of ~10 min. This contradicts other reports of very
fast intrinsic flip–flop [reviewed in Ref. (162)], which suggest that
cholesterol does not require a transport protein to move between
bilayer leaflets. Eckford and Sharom confirmed rapid flip–flop of
two cholesterol analogs in native membrane vesicles and pro-
teoliposomes, faster than the time-resolution of the cholesterol
oxidase assay, and also failed to show Pgp-mediated flip–flop of
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cholesterol (123). Since Pgp mediates ATP-dependent transloca-
tion of SM (44), which has a high affinity for cholesterol (163),
it may indirectly influence cholesterol distribution in membranes.
It is unlikely that Pgp is directly involved in moving cholesterol
between membrane leaflets.
LIPID RAFTS AND PGP
The cholesterol content of the plasma membrane is highly regu-
lated and relatively invariant. However, some domains are selec-
tively enriched in cholesterol, namely lipid rafts and caveolae,
which are characterized by the presence of higher lipid order, lower
density, and detergent resistance (164). In intact cells, dynamic
movement of Pgp into and out of these more ordered, cholesterol-
rich domains could potentially regulate its functions. Pgp has been
proposed to localize in low density raft microdomains and caveo-
lae in some cell and tissue types [for a detailed list, see Ref. (165)].
However, in one MDR cell line, Pgp was present in intermediate
density Brij-96 domains that were biochemically and physically
distinct from both classical low density lipid rafts and caveolae
(166), and in another case, Pgp was found not to be associated
with lipid rafts at all (167). Thus, any proposed role for these
domains in functional modulation of Pgp must necessarily be cell
type-specific. Typically, treatments that break up lipid rafts (e.g.,
MβCD) result in loss of Pgp from raft domains, and a decrease
in its function [for example, see Ref. (168)]. However, interpre-
tation of these results is complicated by the fact that MβCD has
secondary effects besides cholesterol sequestration; it can extract
other membrane components such as phospholipids (169), and
it is also known to inhibit Pgp catalytic function directly (123).
One other source of variation in assessing the association of Pgp
with these domains is the methodology used to isolate lipid rafts.
Several different detergents have been commonly used for their
extraction from intact cells, including Triton X-100, Brij-96, and
Lubrol, and detergent-free approaches using carbonate have also
been employed [see Ref. (165)]. It has been suggested that lipid
rafts domains are concentric layered structures, with different sen-
sitivities to detergent extraction at their periphery compared to the
central core (170). This may explain why Pgp is typically strongly
associated with Lubrol- or Brij-96-based rafts, but less so with
Triton X-100 rafts (171).
Perhaps not surprisingly, Callaghan and co-workers showed
that Pgp was fully functional after reconstitution into liquid-
ordered (lo phase) membranes rich in sphingolipids and choles-
terol, i.e., with a typical “lipid raft” composition (172). The main
difference noted between Pgp behavior in raft-like proteolipo-
somes and in those composed of PC alone was that drugs were
able to stimulate or inhibit ATPase activity at lower concentra-
tions. This is compatible with reports that Pgp binds its substrates
more tightly in less fluid lipid bilayers (122, 124).
DETERGENTS AND MEMBRANE FLUIDIZERS AS PGP
MODULATORS
Lipophilic compounds cross lipid bilayers by a three-step process
involving partitioning into the interfacial region, diffusion
through the hydrophobic core, and desorption from the oppo-
site side of the membrane. Since many compounds, including
Pgp substrates, are localized in specific regions of a lipid bilayer,
the second step may be thought of as flip–flop (173), and is the
slowest, rate-limiting step for movement of amphiphilic species
across membranes. For example, doxorubicin flip–flop across lipid
bilayers occurs with a half-time of ~1 min (174). The ability of sub-
strates and modulators to interact with Pgp may depend on their
ability to flip–flop between membrane leaflets. For example, some
positively charged drugs and peptide modulators cannot interact
with Pgp in intact cells if supplied on the extracellular side, prob-
ably because they have a very low rate of flip–flop to the inner
leaflet (175). However, they can interact with Pgp in membrane
vesicles, where the cytoplasmic leaflet is accessible. In support of
this idea, substrate concentrations were found to be significantly
lower in the cytosolic leaflet of intact cells expressing Pgp than in
the cytosolic leaflet of inside-out membrane vesicles (176).
P-glycoprotein may handle classical modulators in exactly the
same way as drugs, i.e., they are transported with hydrolysis of
ATP (37, 177). The difference in the behavior of modulators and
drugs may be related to their rate of flip–flop across the membrane
(37). Pgp substrates were found to cross lipid bilayers relatively
slowly (half-time for rhodamine 123 of ~3 min), while the trans-
bilayer diffusion rates of several modulators were extremely fast.
Pgp moves drugs and modulators (those that are transported) to
the outer membrane leaflet, or they re-enter it after being moved
to the extracellular medium. The rate of flip–flop to the inner
leaflet is proposed to be slow for substrates, so that Pgp can keep
pace, establish a drug concentration gradient across the mem-
brane, and ultimately cause drug resistance. The long residence
time of substrates in the inner leaflet also allows more opportu-
nity for interaction with Pgp (174). For modulators, the rate of
transbilayer flip–flop is so rapid that Pgp cannot keep pace or
establish a concentration gradient, and MDR cells are not resis-
tant to them. Work by Seelig and co-workers confirmed these ideas
(176). Pgp in intact cells was found to transport substrates at a rate
proportional to that of ATP hydrolysis, however, it could only pre-
vent substrates from entering the cytosol if their rate of diffusion
across the lipid bilayer was slow, in a range similar to that of Pgp-
mediated efflux. This model suggests that for a modulator to be
effective, it should bind to Pgp with high affinity and also have a
high transbilayer diffusion rate (36, 177). If a compound modifies
membrane properties to increase the rate of transbilayer move-
ment of a drug sufficiently, it may be able to circumvent resistance
without interacting specifically with Pgp. Thus, a second class of
Pgp modulators may exist, consisting of agents such as surfactants
and membrane fluidizers. In fact, several compounds that fall into
this category are already known to reverse MDR (e.g., Pluronic
block copolymers, Cremophor EL, Solutol HS15, Tween 80) (143,
178). Surfactants are ubiquitous in cleaning products, and are also
present as additives in food and cosmetics. Since they are typi-
cally of very low toxicity, they may represent a useful class of Pgp
modulators.
Evidence for the idea that Pgp-mediated MDR can be mod-
ulated by acceleration of passive drug permeation across the
plasma membrane is contradictory. Tween 80 and Cremophor EL
inhibited Pgp function in cell monolayers, increasing the apical-to-
basolateral permeability and decreasing the basolateral-to-apical
permeability of the substrate rhodamine 123 (179). These effects
were related to the ability of the surfactants to increase membrane
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fluidity, in contrast with OG, which did not either modulate
membrane fluidity or affect Pgp transport. However,polyoxyethyl-
ene surfactants that reversed MDR actually decreased lipid fluidity
in plasma membrane vesicles from MDR cells, as assessed using
several fluorescent probes (147), whereas surfactants that did not
reverse MDR did not influence membrane fluidity. Low concen-
trations of Pluronic 61 were found to greatly increase the rates of
phospholipid flip–flop and transbilayer movement of doxorubicin
in lipid bilayers (180). Anesthetics (benzyl alcohol, chloroform,
and diethylether) and non-ionic detergents (Tween-20, Nonidet
P-40, and Triton X-100), increase membrane fluidity and the rate
of transbilayer drug flip–flop (144). These compounds also abol-
ish Pgp ATPase activity and drug binding, possibly by increasing
membrane fluidity. Recent work in intact cells reported differ-
ent results from experiments using liposomes and plasma mem-
brane vesicles (146). Anesthetics were found to modulate MDR by
accelerating transbilayer drug movement, whereas Pluronic P85,
Tween-20, Triton X-100, and Cremophor EL had no effect on
drug movement,and modulated MDR by inhibiting Pgp-mediated
efflux. No correlation was found between the ability of surfac-
tants to accelerate drug movement and their membrane fluidizing
effects (146). Thus the molecular mechanism by which surfac-
tants and membrane fluidizers inhibit the action of Pgp is still
very much an open question.
CONCLUSION AND FUTURE PROSPECTS
P-glycoprotein is an unusual transporter, and various aspects of
its function appear to be modulated by the lipid environment in
novel and complex ways. Its mode of action as a hydrophobic
vacuum cleaner and lipid/drug flippase make it especially sensi-
tive to the properties of the surrounding lipid bilayer. Membrane
composition, fluidity, and phase state all appear to be important
parameters affecting Pgp stability, ATP binding, ATP hydrolysis,
drug binding, and drug transport. Substrate interactions with the
lipid bilayer play a critical role in the overall process of drug
binding to Pgp, and are also modulated by the physicochemical
properties of the membrane. It has been proposed that changing
the properties of the host membrane may be a useful approach for
clinical modulation of MDR. Clearly, an enhanced understand-
ing of how all aspects of the Pgp catalytic cycle are affected by
the local lipid microenvironment is essential if this strategy is to
be successful. For example, the relationship between membrane
partitioning and the binding affinity of Pgp substrates suggests
one way to reduce or circumvent drug resistance. If a chemother-
apeutic drug can be chemically modified to reduce its lipid–water
partition coefficient, the ability of Pgp to transport it might be
reduced. This would allow the drug to reach its intracellular tar-
gets, and thus increase its clinical effectiveness. Recent work on
Pgp-membrane interactions has advanced to the point where it is
now possible to measure thermodynamic and kinetic constants for
the various steps of the catalytic cycle in model systems. Although
the relationship between Pgp and its membrane environment is
likely to be much more complex in living cells, this approach
may provide a rational basis for novel strategies to overcome
Pgp-mediated MDR in human tumors. It may also lead to a bet-
ter understanding of the molecular mechanism of this enigmatic
transporter.
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